Toggle navigation
Home
Search
Services
Blog
Contact
About
Therapy of Ovarian Cancer with 9-Nitrocamptothecin
Pantazis, Panayotis
Stehlin Foundation for Cancer Research, Houston, TX, United States
Search 7 grants from Panayotis Pantazis
Search grants from Stehlin Foundation for Cancer Research
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Mechanisms Underlying Innate Odor Fear
Centers of Excellence, Other
Mechanism of Fluoride Resistance by Cariogenic Bacteria
Surgery and Bioengineering Study Section
Opportunities to Advance Success in the Sciences (OASIS)
Recently added grants:
Omics for TB: Response to Infection and Treatment
Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons
Adminstrative Core
Technology Core
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21CA071485-01
Application #
2115096
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-09-30
Project End
1998-09-29
Budget Start
1996-09-30
Budget End
1997-09-29
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Stehlin Foundation for Cancer Research
Department
Type
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77025
Related projects
NIH 1997
R21 CA
Therapy of Ovarian Cancer with 9-Nitrocamptothecin
Giovanella, Beppino C. / Stehlin Foundation for Cancer Research
NIH 1996
R21 CA
Therapy of Ovarian Cancer with 9-Nitrocamptothecin
Pantazis, Panayotis / Stehlin Foundation for Cancer Research
Publications
Verschraegen, Claire F; Hu, Wei; Du, Yu et al.
(2003)
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Clin Cancer Res 9:845-52
Comments
Be the first to comment on Panayotis Pantazis's grant